Managing Haemophilic Arthropathy in People With Haemophilia in Japan: An Informal Consensus.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Kumiko Ono has received honoraria from Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. Azusa Nagao has received investigator‐initiated research/education grant funding from Bayer Yakuhin Ltd., Pfizer Japan Inc., and Chugai Pharmaceutical Co., Ltd. and honoraria from Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Fujimoto Pharmaceutical Corporation, KM Biologics, Pfizer Japan Inc., Novo Nordisk Pharma Ltd., and CSL Behring; and is a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics. Yusuke Inagaki has received specified clinical trial funding from MediaMart Co., Ltd.; research funding from Chugai Pharmaceutical Co., Ltd., Johnson & Johnson K.K., KM Biologics, Olympus Terumo Biomaterials Corp., and Zimmer Biomet; and honoraria from Asahi Kasei Pharma Corporation, Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Healios K.K., Hisamitsu Pharmaceutical Co., Johnson & Johnson K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd.; and is a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics. Kagehiro Amano has received research funding from KM Biologics; consulting fees from Chugai Pharmaceutical Co., Ltd.; and payment or honoraria from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Novo Nordisk Pharma Ltd., KM Biologics, Japan Blood Products Organization, Sanofi K.K., Takeda Pharmaceutical Co., Ltd., CSL Behring, Pfizer Japan Inc., and Fujimoto Pharmaceutical Corporation; has participated on a safety monitoring board or advisory board for Chugai Pharmaceutical Co., Ltd.; and is an endowed chair for CSL Behring. Miwa Goto has received honoraria for speakers’ bureaus from Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., CSL Behring, and Novo Nordisk Pharma Ltd. Chiai Nagae has received honoraria for speakers' bureaus from Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. Akihiro Sawada has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., CSL Behring, Sanofi K.K., KM Biologics, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. Rie Shirayama has received consulting fees from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., and Pfizer Japan Inc., and honoraria for speakers bureaus from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Novo Nordisk Pharma Ltd., KM Biologics, CSL Behring, and Fujimoto Pharmaceutical Corporation; has participated on advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K.; and the institution that employs Rie Shirayama has received grants from Chugai Pharmaceutical Co., Ltd. Nobuaki Suzuki has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd., CSL Behring, Bayer Yakuhin Ltd., Pfizer Japan Inc., Japan Blood Products Organization, and KM Biologics. Masahiro Takeyama has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, Bayer Yakuhin Ltd., and Pfizer Japan Inc.; has received investigator‐initiated research grant funding from Chugai Pharmaceutical Co., Ltd. and Japan Blood Products Organization; and has participated on advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. Hideyuki Takedani has received honoraria from Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd.; has an advisory role with Novo Nordisk Pharma Ltd., and Chugai Pharmaceutical Co., Ltd.; has received honoraria for speakers’ bureaus from Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd., Sanofi K.K., KM Biologics, and Asahi Kasei Corporation. Makoto Kaneda, Kenichiro Makino, and Naoya Yamasaki have no conflicts of interest to declare. 14. BMC Musculoskelet Disord. 2018 May 22;19(1):162. doi: 10.1186/s12891-018-2080-0. Range of motion after total knee arthroplasty in hemophilic arthropathy. Kubeš R(1), Salaj P(2), Hromádka R(3), Včelák J(4), Kuběna AA(5), Frydrychová M(4), Magerský Š(4), Burian M(4), Ošťádal M(4), Vaculik J(4). Author information: (1)Department of Orthopaedics, 1st Faculty of Medicine, Charles University and Na Bulovce Hospital, Budínova 2, 180 81, Prague 8, Czech Republic. rastho@gmail.com. (2)Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University and Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12802, Prague 2, Czech Republic. (3)Department of Orthopaedics, 1st Faculty of Medicine, Charles University and Motol University Hospital, Úvalu 84, 15006, Prague 5, Czech Republic. (4)Department of Orthopaedics, 1st Faculty of Medicine, Charles University and Na Bulovce Hospital, Budínova 2, 180 81, Prague 8, Czech Republic. (5)Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05, Hradec Králové, Czech Republic. BACKGROUND: Outcomes of total knee replacement in cases of hemophilic patients are worse than in patients who undergo operations due to osteoarthritis. Previous publications have reported varying rates of complications in hemophilic patients, such as infection and an unsatisfactory range of motion, which have influenced the survival of prostheses. Our retrospective study evaluated the data of hemophilic patients regarding changes in the development of the range of motion. METHODS: The data and clinical outcomes of 72 total knee replacements in 45 patients with hemophilia types A and B were reviewed retrospectively. Patients were operated between 1998 and 2013. All of the patients were systematically followed up to record the range of motion and other parameters before and after surgery. RESULTS: The mean preoperative flexion contracture was 17° ± 11° (range, 0°-40°), and it was 7° ± 12° (range, 0°-60°) postoperatively. The mean flexion of the knee was 73° ± 30° (range, 5°-135°) before the operation and 80° ± 19° (range, 30°-110°) at the last follow-up. The mean range of motion was 56° ± 34° (range, 0°-130°) before the operation and 73° ± 24° (range, 10°-110°) at the last follow-up. CONCLUSIONS: Statistical analysis suggested that the range of motion could be improved until the 9th postoperative week. The patient should be operated on until the flexion contracture reaches 22° to obtain a contracture